• Revenue increased 916% to $375,551
• Net loss attributable to members increased 226% to $5,707,134
• Initiated pivotal U.S. FDA registrational study for autism with 91 children enrolled by quarter end

BlinkLab Limited is a pioneering digital healthcare company leveraging smartphones, computer vision, Artificial Intelligence (AI), and Machine Learning (ML) to transform the diagnosis of neurodevelopmental conditions such as autism and ADHD. In the 2025 financial year, the company achieved significant operational and clinical milestones across the United States and Europe, advancing its mission to deliver earlier, more accurate, and more accessible diagnostics. The company reported a 916% increase in revenue to $375,551 and a 226% increase in net loss attributable to members to $5,707,134. The loss mainly reflects product development costs, salary, corporate, regulatory and contract costs as a result of the company's focus on research and development activities.Building on the preparatory regulatory and site activation work of late 2024, BlinkLab initiated its pivotal U.S. FDA registrational study for autism in early 2025. The trial commenced with a 100-participant pilot phase, designed to de-risk the larger multi-site study of up to 1,000 subjects across the United States. By March 2025, clinical recruitment had accelerated, with the first U.S. child participant tested and 91 children enrolled by quarter end, reflecting a faster-than-expected recruitment pace.